Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepat… Read more
Assembly Biosciences Inc (ASMB) - Net Assets
Latest net assets as of September 2025: $182.69 Million USD
Based on the latest financial reports, Assembly Biosciences Inc (ASMB) has net assets worth $182.69 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($240.00 Million) and total liabilities ($57.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $182.69 Million |
| % of Total Assets | 76.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | -86.13% |
| 10-Year Change | -71.91% |
| Growth Volatility | 75.22 |
Assembly Biosciences Inc - Net Assets Trend (2008–2024)
This chart illustrates how Assembly Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Assembly Biosciences Inc (2008–2024)
The table below shows the annual net assets of Assembly Biosciences Inc from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $33.36 Million | -18.83% |
| 2023-12-31 | $41.10 Million | -50.28% |
| 2022-12-31 | $82.66 Million | -51.07% |
| 2021-12-31 | $168.93 Million | -29.78% |
| 2020-12-31 | $240.58 Million | -11.95% |
| 2019-12-31 | $273.22 Million | +29.70% |
| 2018-12-31 | $210.65 Million | +86.22% |
| 2017-12-31 | $113.12 Million | +41.62% |
| 2016-12-31 | $79.88 Million | -32.73% |
| 2015-12-31 | $118.74 Million | +102.73% |
| 2014-12-31 | $58.57 Million | +139.12% |
| 2013-12-31 | $24.49 Million | +37.53% |
| 2012-12-31 | $17.81 Million | -48.43% |
| 2011-12-31 | $34.53 Million | +197.03% |
| 2010-12-31 | $11.63 Million | +187.00% |
| 2009-12-31 | $-13.36 Million | -41.30% |
| 2008-12-31 | $-9.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Assembly Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 81257067600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.02% |
| Other Comprehensive Income | $-211.00K | -0.63% |
| Other Components | $859.49 Million | 2576.48% |
| Total Equity | $33.36 Million | 100.00% |
Assembly Biosciences Inc Competitors by Market Cap
The table below lists competitors of Assembly Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Momentum Group AB (publ)
ST:MMGR-B
|
$205.25 Million |
|
Artius II Acquisition Inc. Units
NASDAQ:AACBU
|
$205.28 Million |
|
Beijing Succeeder Technology Inc
SHG:688338
|
$205.28 Million |
|
Great Tree Pharmacy Co Ltd
TWO:6469
|
$205.37 Million |
|
X-FAB Silicon Foundries SE
PINK:XFABF
|
$205.23 Million |
|
UniTest Incorporation
KQ:086390
|
$205.11 Million |
|
Zhengzhou J and T Hi Tech Co
SHE:300845
|
$205.10 Million |
|
INSPUR INTL NEW HD-01
F:L1CC
|
$205.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Assembly Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 41,097,000 to 33,359,000, a change of -7,738,000 (-18.8%).
- Net loss of 40,177,000 reduced equity.
- New share issuances of 29,294,000 increased equity.
- Other comprehensive income decreased equity by 130,000.
- Other factors increased equity by 3,275,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-40.18 Million | -120.44% |
| Share Issuances | $29.29 Million | +87.81% |
| Other Comprehensive Income | $-130.00K | -0.39% |
| Other Changes | $3.27 Million | +9.82% |
| Total Change | $- | -18.83% |
Book Value vs Market Value Analysis
This analysis compares Assembly Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $-112.12 | $27.52 | x |
| 2009-12-31 | $-150.13 | $27.52 | x |
| 2010-12-31 | $93.77 | $27.52 | x |
| 2011-12-31 | $179.60 | $27.52 | x |
| 2012-12-31 | $69.97 | $27.52 | x |
| 2013-12-31 | $63.15 | $27.52 | x |
| 2014-12-31 | $83.69 | $27.52 | x |
| 2015-12-31 | $75.62 | $27.52 | x |
| 2016-12-31 | $46.37 | $27.52 | x |
| 2017-12-31 | $63.73 | $27.52 | x |
| 2018-12-31 | $92.39 | $27.52 | x |
| 2019-12-31 | $77.88 | $27.52 | x |
| 2020-12-31 | $60.63 | $27.52 | x |
| 2021-12-31 | $46.84 | $27.52 | x |
| 2022-12-31 | $20.49 | $27.52 | x |
| 2023-12-31 | $8.98 | $27.52 | x |
| 2024-12-31 | $5.56 | $27.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Assembly Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -120.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -140.87%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 3.57x
- Recent ROE (-120.44%) is below the historical average (-68.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.84 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.20 Million |
| 2010 | -131.52% | 0.00% | 0.00x | 1.26x | $-16.45 Million |
| 2011 | -99.46% | 0.00% | 0.00x | 1.07x | $-37.80 Million |
| 2012 | -139.19% | 0.00% | 0.00x | 1.15x | $-26.57 Million |
| 2013 | -79.22% | 0.00% | 0.00x | 1.11x | $-21.85 Million |
| 2014 | -40.62% | 0.00% | 0.00x | 1.22x | $-29.65 Million |
| 2015 | -23.96% | 0.00% | 0.00x | 1.13x | $-40.33 Million |
| 2016 | -55.41% | 0.00% | 0.00x | 1.23x | $-52.25 Million |
| 2017 | -37.84% | -474.66% | 0.05x | 1.50x | $-54.12 Million |
| 2018 | -43.08% | -613.02% | 0.06x | 1.27x | $-111.82 Million |
| 2019 | -35.73% | -611.63% | 0.05x | 1.27x | $-124.96 Million |
| 2020 | -25.83% | -78.57% | 0.28x | 1.18x | $-86.21 Million |
| 2021 | -76.87% | -2076.35% | 0.03x | 1.13x | $-146.75 Million |
| 2022 | -111.38% | 0.00% | 0.00x | 1.23x | $-100.34 Million |
| 2023 | -148.98% | -854.78% | 0.05x | 3.33x | $-65.34 Million |
| 2024 | -120.44% | -140.87% | 0.24x | 3.57x | $-43.51 Million |
Industry Comparison
This section compares Assembly Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Assembly Biosciences Inc (ASMB) | $182.69 Million | 0.00% | 0.31x | $205.25 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |